SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $791,347,834 |
| Positions | 149 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| VIKING THERAPEUTICS INC | VKTX | COM | $47,623,408 | 1,220,800 |
| ABIVAX SA | ABVX | SPONSORED ADS | $46,534,392 | 349,200 |
| BRISTOL-MYERS SQUIBB CO | BMY | COM | $34,572,000 | 600,000 |
| ABIVAX SA | ABVX | SPONSORED ADS | $33,634,824 | 252,400 |
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $28,711,030 | 52,989 |
| REVOLUTION MEDICINES INC | RVMD | COM | $26,072,747 | 139,218 |
| ABIVAX SA | ABVX | SPONSORED ADS | $21,598,038 | 163,644 |
| COGENT BIOSCIENCES INC | COGT | COM | $19,104,797 | 493,664 |
| BRISTOL-MYERS SQUIBB CO | BMY | COM | $19,049,172 | 330,600 |
| BRIDGEBIO PHARMA INC | BBIO | NOTE 1.750% 3/0 | $18,620,000 | 250,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.